The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Effect of prior therapies on the activity of imetelstat in transfusion-dependent R/R LR-MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses an analysis of the Phase II/III IMerge trial (NCT02598661), which explored the efficacy of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS) who have failed prior treatments. Prof. Platzbecker notes that imetelstat remains effective in patients who have failed erythropoiesis-stimulating agents (ESAs), luspatercept, and lenalidomide, with response rates slightly lower in those who received prior hypomethylating agent (HMA)-based therapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: Travel support, Research Funding; MDS Foundation: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Consultancy, Research Funding; Curis: Consultancy, Honoraria, Research Funding; Geron: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding.
